Editorial: ANCA-associated vasculitis treatment: outcomes and complications

Editorial on the Research Topic
ANCA-associated vasculitis treatment: outcomes and complications

ANCA-associated vasculitis (AAV) is a group of rare, systemic, autoimmune diseases that are characterized by the inflammation of the small blood vessels and the usual presence of circulating ANCA antibodies (1). Thanks to advancements in treatment options, the prognosis for these diseases has significantly improved, and the risk of relapse has decreased (2). There is also an increased need to identify clinical subtypes within the classical AAV classification that would, based on individual disease traits and particular biomarkers, benefit from specific therapeutic approaches (3). Explored biomarkers might potentially allow for more personalized plans for patients’ retreatment by predicting disease activity or flares before clinical relapse (4).

The aim of this Research Topic is to describe the state of the art in AAV prognostic tools, treatment goals, and potential biomarker use. This Research Topic contains 5 articles, including two original research publications and three reviews, which nicely balance biomarker research with subtype clustering and specific treatment modalities, supporting the importance of this topic.

Moving beyond earlier classification systems of rare diseases is necessary even within specific clinical phenotypes in order to have better prognostic information, which could guide treatment decisions. In their multicenter cohort study, Okazaki et al. identified four unique subgroups of microscopic polyangiitis (MPA) patients with different outcomes. The two out these four subgroups, one with renal involvement and diffuse alveolar hemorrhage (DAH) and the other including elderly onset patients with systemic inflammation, had the worst overall survival, and the first one highest chance for ESKD. This suggests the importance of pooling data and conducting cluster analyses, as demonstrated in the works by the FAIRVASC consortium (5). An individualized treatment approach for each subgroup may be required in order to improve survival and reduce the risk of ESKD. (Okazaki et al.)

In their interesting review, Alberici et al. explored the challenges of defining treatment goals for AAV patients. Treatment advances in recent decades improved overall patient survival, reduced end-organ damage and turned AAVs into chronic diseases. The authors also noted that preserving patients’ quality of life has become as important as controlling disease activity. This requires the clinicians to balance both clinical and patient needs. One of the most important aspects is reducing treatment side effects by developing more targeted therapies. The future of successful management of AAV will require reducing AAV organ damage and achieving patient satisfaction (Federici A et al.).

Treatment goals often depend on assessing disease activity, for which tools are still limited. Therefore, there is a growing need for adequate and validated candidate biomarkers. On this note, Marvisi et al., in their detailed review, explored a variety of serological, cellular, and urinary biomarkers, with a focus on their use in assessing disease activity, disease-related damage, and prognosis. It is increasingly plausible that the future of personalized treatment and disease activity assessment will be based on biomarker panels rather than individual biomarkers. However, at the moment, according to the authors, there are two promising, commercially available biomarkers: urinary sCD163 and MCP-1 (6, 7). Both appear to distinguish well between active renal AAV and remission (Marvisi et al.).

Regarding eosinophilic granulomatosis with polyangiitis (EGPA), the original study by Shiomi et al. and the review of Lazzeroni et al. complement each other well. Both explored the role of biologics in treating EGPA.

In their REVEAL study, Shiomi et al. showed that mepolizumab contributes to both disease activity control and glucocorticoid (GC) dose reduction in their cohort of patients with EGPA, which may increase patient survival and reduce GC side effects.

This was further reaffirmed in a detailed review presented by (Lazzeroni et al.). The authors reviewed treatments consisting of benralizumab, mepolizumab, and reslizumab protocols. All of these anti-IL-5/IL-5 receptor drugs have been shown to be effective in remission control and corticosteroid tapering. The analyzed data strongly suggest the benefits of integrating anti IL-5/IL-5 receptor therapies into EGPA treatment strategies to both improve patient outcomes and reduce the side effects of prolonged GC therapy. However, the challenge remains in determining when to initiate anti-IL5/IL-5R therapy, as this has not been uniformly addressed across the included studies.

In conclusion, this Research Topic collects studies highlighting the current state of the art in the field of AAVs, together with original manuscripts identifying both treatment options and new ways of clustering AAVs. These contributions aim to advance prognostic tools and contribute to further progress in this field. We believe that readers will gain a better understanding of this topic (Shiomi et al.) (Lazzeroni et al.).

Author contributions

MC: Writing – original draft, Writing – review & editing. LS: Writing – review & editing. MU: Writing – review & editing. GE: Writing – review & editing.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Generative AI statement

The author(s) declare that no Generative AI was used in the creation of this manuscript.

Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

1. Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, et al. Revised international chapel hill consensus conference nomenclature of vasculitides. Arthritis Rheumatol. (2012) 65:1–11. doi: 10.1002/art.37715

PubMed Abstract | Crossref Full Text | Google Scholar

2. Alberici F and Jayne DRW. Impact of rituximab trials on the treatment of ANCA-associated vasculitis. Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc Eur Ren Assoc. (2014) 29:1151–9. doi: 10.1093/ndt/gft318

PubMed Abstract | Crossref Full Text | Google Scholar

3. Tedesco M, Gallieni M, Pellegata F, Cozzolino M, and Alberici F. Update on ANCA-associated vasculitis: from biomarkers to therapy. J Nephrol. (2019) 32:871–82. doi: 10.1007/s40620-019-00628-9

PubMed Abstract | Crossref Full Text | Google Scholar

4. Charles P, Terrier B, Perrodeau É, Cohen P, Faguer S, Huart A, et al. Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2). Ann Rheum Dis. (2018) 77:1143–9. doi: 10.1136/annrheumdis-2017-212878

PubMed Abstract | Crossref Full Text | Google Scholar

5. Gisslander K, White A, Aslett L, Hrušková Z, Lamprecht P, Musiał J, et al. Data-driven subclassification of ANCA-associated vasculitis: model-based clustering of a federated international cohort. Lancet Rheumatol. (2024) 6:e762–70.

PubMed Abstract | Google Scholar

6. Moran SM, Scott J, Clarkson MR, Conlon N, Dunne J, Griffin MD, et al. The clinical application of urine soluble CD163 in ANCA-associated vasculitis. J Am Soc Nephrol. (2021) 32:2920–32. doi: 10.1681/ASN.2021030382

PubMed Abstract | Crossref Full Text | Google Scholar

7. Kronbichler A, Kerschbaum J, Gründlinger G, Leierer J, Mayer G, and Rudnicki M. Evaluation and validation of biomarkers in granulomatosis with polyangiitis and microscopic polyangiitis. Nephrol Dial Transplant. (2016) 31:930–6. doi: 10.1093/NDT/GFV336

PubMed Abstract | Crossref Full Text | Google Scholar